The three largest pharmacy benefit managers (PBMs) inflated the price of specialty generic drugs beyond their costs of ...
The new document focuses on the influence of PBMs over the market for specialty generic drugs for illnesses like cancer, ...
Pharmacy benefit managers, which serve as the middlemen between drug makers, insurers and pharmacies, reaped $7.3 billion in ...
From 2017 to 2022, the companies marked up prices at their pharmacies by hundreds or thousands of percent, netting them $7.3 ...
The three biggest pharmacy benefit managers made more than $7.3 billion over five years marking up the prices of specialty ...
For the second time in less than a year, the FTC has released a highly critical report of pharmacy benefit managers, or PBMs.
The FDC released a second highly critical report of PBMs, which may provide further impetus for legislative action to curb ...
The nation's three largest pharmacy benefit managers have significantly marked up the prices of certain medicines, including ...
"While this information is theoretically available to the public, institutional owners' holdings are challenging to identify ...
The U.S. Federal Trade Commission (FTC) has slammed pharmacy benefit managers (PBMs) owned by UnitedHealth ($UNH), CVS Health ...
A new report from the Federal Trade Commission is uncovering what appears to be a major driver of the high cost of ...
Regulators published their most detailed findings yet on how some of the nation’s largest companies profited from "excess" ...